Home » Stocks » Mylan

Mylan N.V. (MYL)

Stock Price: $16.36 USD -0.06 (-0.37%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $16.26 -0.10 (-0.61%) Aug 7, 7:32 PM

Stock Price Chart

Key Info

Market Cap 8.46B
Revenue (ttm) 11.50B
Net Income (ttm) 270.50M
Shares Out 516.95M
EPS (ttm) 0.52
PE Ratio 31.46
Forward PE 3.81
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $16.36
Previous Close $16.42
Change ($) -0.06
Change (%) -0.37%
Day's Open 16.21
Day's Range 16.01 - 16.42
Day's Volume 3,873,739
52-Week Range 12.75 - 23.11

More Stats

Market Cap 8.46B
Enterprise Value 20.33B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 516.95M
Float 513.55M
EPS (basic) 0.53
EPS (diluted) 0.52
FCF / Share 3.18
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.18%
FCF Yield 19.41%
Payout Ratio n/a
Shares Short 32.73M
Short Ratio 5.69
Short % of Float 7.97%
Beta 1.53
PE Ratio 31.46
Forward PE 3.81
P/FCF Ratio 5.15
PS Ratio 0.74
PB Ratio 0.75
Revenue 11.50B
Operating Income 914.90M
Net Income 270.50M
Free Cash Flow 1.64B
Net Cash -11.87B
Net Cash / Share -22.96
Gross Margin 39.57%
Operating Margin 7.95%
Profit Margin 2.40%
FCF Margin 14.27%
ROA 3.49%
ROE 2.29%
ROIC 5.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 6
Overweight 1
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(34.90% upside)
Current: $16.36
Target: 22.07
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth0.58%-3.98%7.5%17.47%22.15%11.73%1.66%10.87%12.46%-
Gross Profit3,8984,0024,7834,6974,2163,5283,0402,9082,5632,217
Operating Income7169061,4376991,4611,3531,1361,1091,005722
Net Income16.80353696480848929624641537345
Shares Outstanding516515535513472374383415431324
Earnings Per Share0.030.681.300.921.702.341.581.521.220.68
EPS Growth-95.59%-47.69%41.3%-45.88%-27.35%48.1%3.95%24.59%79.41%-
Operating Cash Flow1,8042,3422,0652,0472,0091,0151,107949720931
Capital Expenditures-213-252-276-390-363-325-309-289-280-188
Free Cash Flow1,5912,0901,7891,6571,646690797660441744
Cash & Equivalents4763882929991,236226291350375715
Total Debt12,72213,86314,72115,5397,3748,5048,0305,7345,2995,433
Net Cash / Debt-12,247-13,475-14,429-14,541-6,138-8,278-7,739-5,384-4,924-4,718
Book Value11,88412,16713,30811,1169,7643,2562,9423,3413,4923,602
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mylan N.V.
Country United Kingdom
Employees 35,000
CEO Heather M. Bresch

Stock Information

Ticker Symbol MYL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: MYL


Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.